Lenvima
Named-patient access overview. Lenvima is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Lenvima (lenvatinib) is an oral multikinase tyrosine kinase inhibitor developed by Eisai that blocks VEGFR1-3, FGFR1-4, PDGFR-alpha, KIT, and RET. The US Food and Drug Administration first approved Lenvima in February 2015 for locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer, with subsequent approvals in advanced renal cell carcinoma (in combination with everolimus or pembrolizumab), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (in combination with pembrolizumab). It is given as a once-daily oral capsule, with the starting dose set by indication and adjusted for body weight, hepatic function, and tolerability. Lenvima is prescribed and monitored by medical oncology specialists in outpatient cancer-centre settings.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Lenvima
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Lenvima is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Lenvima in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Lenvima
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Lenvima if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Lenvima for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Lenvima through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Lenvima. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Lenvima through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Lenvima to a patient?
Reserve Meds sources Lenvima from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Lenvima cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Lenvima?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.